Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an interface for clinicians to track and trace the patient's treatment progress. The company was incorporated in 2012 and is based in Copenhagen, Denmark. Brain+ A/S was formerly a subsidiary of Brain+ Holding ApS.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Buy
Sell